TACT vs. ZEPP, LTRX, OSS, MKFG, SILC, ALOT, INVE, QMCO, LINK, and INTZ
Should you be buying TransAct Technologies stock or one of its competitors? The main competitors of TransAct Technologies include Zepp Health (ZEPP), Lantronix (LTRX), One Stop Systems (OSS), Markforged (MKFG), Silicom (SILC), AstroNova (ALOT), Identiv (INVE), Quantum (QMCO), Interlink Electronics (LINK), and Intrusion (INTZ). These companies are all part of the "computer hardware" industry.
TransAct Technologies vs. Its Competitors
TransAct Technologies (NASDAQ:TACT) and Zepp Health (NYSE:ZEPP) are both small-cap computer hardware companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.
In the previous week, Zepp Health had 5 more articles in the media than TransAct Technologies. MarketBeat recorded 5 mentions for Zepp Health and 0 mentions for TransAct Technologies. TransAct Technologies' average media sentiment score of 1.87 beat Zepp Health's score of 0.31 indicating that TransAct Technologies is being referred to more favorably in the media.
TransAct Technologies has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Zepp Health has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
TransAct Technologies currently has a consensus target price of $5.00, indicating a potential upside of 39.08%. Zepp Health has a consensus target price of $13.87, indicating a potential upside of 3.97%. Given TransAct Technologies' higher probable upside, analysts plainly believe TransAct Technologies is more favorable than Zepp Health.
TransAct Technologies has a net margin of -19.25% compared to Zepp Health's net margin of -44.54%. TransAct Technologies' return on equity of -4.32% beat Zepp Health's return on equity.
TransAct Technologies has higher earnings, but lower revenue than Zepp Health. TransAct Technologies is trading at a lower price-to-earnings ratio than Zepp Health, indicating that it is currently the more affordable of the two stocks.
74.5% of TransAct Technologies shares are owned by institutional investors. Comparatively, 52.6% of Zepp Health shares are owned by institutional investors. 16.5% of TransAct Technologies shares are owned by company insiders. Comparatively, 36.0% of Zepp Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
TransAct Technologies beats Zepp Health on 10 of the 15 factors compared between the two stocks.
Get TransAct Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TACT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TACT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransAct Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:TACT) was last updated on 7/18/2025 by MarketBeat.com Staff
